Thanks Sammy on Type C definition.
Re 'early consultations on use of biomarker'...
End points for DMD will be straight forward imo. We have solid PUL2 efficacy data from P2 - and outstanding comparison vs natural history data.
Just as important outcome would be for ANP to ram home the CD49d thesis for other indications....
We need FDA to be 'full bottle' on all things CD49d..and their buy-in for a potential 'platform' approach that could benefit other MD indications - FAST.
For a Big Pharma whale, a FDA backed 'platform' approach would hold much more value than a single DMD program.
.
US deal for ATL1102, page-164
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $85.01M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $103.7K | 1.237M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 204084 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 280000 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |